Vertex Pharmaceuticals Valuation
| VX1 Stock | EUR 375.00 9.50 2.47% |
At this time, the company appears to be overvalued. Vertex Pharmaceuticals has a current Real Value of €315.0 per share. The regular price of the company is €375.0. Our model measures the value of Vertex Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 257.09 M, return on equity of 0.28, and Operating Margin of 0.49 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vertex Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Vertex Pharmaceuticals is based on 3 months time horizon. Increasing Vertex Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vertex stock is determined by what a typical buyer is willing to pay for full or partial control of Vertex Pharmaceuticals Incorporated. Since Vertex Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vertex Stock. However, Vertex Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 375.0 | Real 315.0 | Hype 375.0 | Naive 362.05 |
The real value of Vertex Stock, also known as its intrinsic value, is the underlying worth of Vertex Pharmaceuticals Company, which is reflected in its stock price. It is based on Vertex Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Vertex Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Vertex Pharmaceuticals Incorporated helps investors to forecast how Vertex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vertex Pharmaceuticals more accurately as focusing exclusively on Vertex Pharmaceuticals' fundamentals will not take into account other important factors: Vertex Pharmaceuticals Total Value Analysis
Vertex Pharmaceuticals Incorporated is at this time estimated to have takeover price of 67.44 B with market capitalization of 70.82 B, debt of 656.95 M, and cash on hands of 3.95 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Vertex Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
67.44 B | 70.82 B | 656.95 M | 3.95 B |
Vertex Pharmaceuticals Investor Information
About 96.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.42. Vertex Pharmaceuticals recorded earning per share (EPS) of 11.89. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Based on the key indicators related to Vertex Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Vertex Pharmaceuticals Incorporated is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Vertex Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vertex Pharmaceuticals has an asset utilization ratio of 49.2 percent. This implies that the Company is making €0.49 for each dollar of assets. An increasing asset utilization means that Vertex Pharmaceuticals Incorporated is more efficient with each dollar of assets it utilizes for everyday operations.Vertex Pharmaceuticals Ownership Allocation
Vertex Pharmaceuticals shows a total of 257.09 Million outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals Incorporated as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vertex Pharmaceuticals Profitability Analysis
The company reported the revenue of 8.93 B. Net Income was 3.32 B with profit before overhead, payroll, taxes, and interest of 5.32 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Vertex Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Vertex Pharmaceuticals and how it compares across the competition.
About Vertex Pharmaceuticals Valuation
The stock valuation mechanism determines Vertex Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Vertex Pharmaceuticals. We calculate exposure to Vertex Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vertex Pharmaceuticals's related companies.Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people.
8 Steps to conduct Vertex Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vertex Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vertex Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Vertex Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Vertex Pharmaceuticals' revenue streams: Identify Vertex Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Vertex Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Vertex Pharmaceuticals' growth potential: Evaluate Vertex Pharmaceuticals' management, business model, and growth potential.
- Determine Vertex Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vertex Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |